NEKTAR THERAPEUTICS INDEMNITY AGREEMENTNektar Therapeutics • March 21st, 2005 • Nektar Therapeutics • Pharmaceutical preparations • Delaware
THIS AGREEMENT is made and entered into this day of , 2005 by and between NEKTAR THERAPEUTICS, a Delaware corporation (the “Corporation”), and (“Agent”).
NEKTAR THERAPEUTICS (a Delaware corporation) PURCHASE AGREEMENTNektar Therapeutics • September 28th, 2005 • Nektar Therapeutics • Pharmaceutical preparations • New York
The Notes will be convertible into fully paid, nonassessable shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), on the terms, and subject to the conditions, set forth in the Indenture (as defined below). As used herein, “Conversion Shares” means the shares of Common Stock into which the Notes are convertible. The Notes will be issued pursuant to an Indenture (the “Indenture”) to be dated as of the First Delivery Date (as defined in Section 2(a)), between the Company and J.P. Morgan Trust Company, National Association, as trustee (the “Trustee”).
